Castle Biosciences, Inc.
METHODS FOR PREDICTING RISK OF RECURRENCE AND/OR METASTASIS IN SOFT TISSUE SARCOMA

Abstract:

The disclosure related to the development of a gene expression profile to predict soft tissue sarcoma (STS) recurrence, distant metastasis, or both. Analyses identified a 36-gene gene expression profile able to accurately predict risk in a cohort of soft tissue sarcoma tumors independent of histologic and pathologic grade. This discovery offers an opportunity to enhance current staging of STS to identify patients who have a higher risk of recurring, distant metastasis, or both.